LCTX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

LC

Mkt Cap

$250.1M

Volume

1.22M

Next Earnings

November 5th

Loading chart

LC

LCTXLineage Cell Therapeutics, Inc.

LCTX

Pay with—

Available Balance0.00

LC

Mkt Cap

$247.4M

Volume

1.22M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative MarketsCell-based therapies are emerging as a transformative approach in healthcare, with the global cell therapy market expected to grow from $4.7 billion in 2023 to over $20 billion by 2030. Several biotech companies announced significant milestones: Avaí Bio and Austrianova completed a Master Cell Bank for α-Klotho anti-aging therapy; Geron presented real-world evidence for RYTELO in myelodysplastic syndromes; BioAge Labs reported Phase 1 results for BGE-102 showing strong inflammatory biomarker reductions; Lineage Cell Therapeutics presented 3-year data for OpRegen cell therapy in geographic atrophy; and Fate Therapeutics advanced FT819 CAR T-cell therapy with FDA recognition.Benzinga · May 20, 2026

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated CellsThe longevity biotech market is expanding rapidly, projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034. Multiple companies are advancing cell and gene therapies targeting age-related diseases: Lineage Cell Therapeutics is developing islet therapy for Type 1 diabetes, Ocugen reported 46% lesion reduction in age-related macular degeneration, Vertex is advancing stem cell-derived islet therapy toward regulatory submissions, and Longeveron published positive Phase 2b data for age-related frailty treatment.Benzinga · Apr 10, 2026

A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.Avaí Bio announced it has initiated manufacturing of a Master Cell Bank of genetically modified cells that overexpress the α-Klotho protein, a key anti-aging protein that naturally declines by 50% after age 40. The milestone represents a transition from research to production infrastructure for their Klothonova anti-aging platform using Cell-in-a-Box® encapsulation technology. The cell therapy sector is rapidly expanding, with the global market projected to grow from $10.4 billion to over $45 billion by 2035.Benzinga · Mar 18, 2026

Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell RestorationThe healthcare sector is experiencing a structural shift toward regenerative medicine and longevity infrastructure, valued at $27 trillion by 2030. Several biotech companies are advancing cell therapy and gene-targeted treatments: Avant Technologies presented cell encapsulation technology for diabetes at a European symposium, MannKind received FDA label updates for Afrezza inhaled insulin, Altimmune gained FDA Breakthrough Therapy Designation for pemvidutide in liver disease, Lineage Cell Therapeutics received a gene-edited cell line from Factor Bioscience, and Arrowhead Pharmaceuticals initiated a Phase 1/2a trial for a dual-gene silencing RNAi therapeutic for cardiovascular disease.Benzinga · Jan 29, 2026

W.P. Carey (WPC) Q2 AFFO Jumps 9.4%W.P. Carey, a diversified net lease REIT, reported Q2 2025 earnings with strong revenue growth and AFFO per share, despite experiencing net income decline due to non-cash market adjustments. The company raised full-year guidance and increased quarterly dividend.The Motley Fool · Jul 30, 2025

Refrigerated Warehousing Market Revenues to Grow from $85 Billion in 2024 to $241 Billion by 2030 - Led by Lineage, Conestoga Cold Storage, Americold Logistics, NewCold Cooperatief UA, and Tippmann GroupThe global refrigerated warehousing market is expected to grow significantly, driven by the surge in e-commerce, particularly in the grocery and food sectors, as well as advancements in cold storage technologies and the rising demand for temperature-sensitive products.GlobeNewswire Inc. · Feb 11, 2025

ORBCOMM joins Move to -15°C coalition to promote cold chain sustainabilityORBCOMM has joined the Move to -15°C campaign as a technology provider to help track and share the telematics data that will help quantify the initiative's impact. The Move to -15°C is a coalition of industry leaders committed to changing the global temperature that frozen food is stored and transported at from -18°C to -15°C, which could cut carbon emissions by 17.7 million metric tonnes and reduce energy consumption by 25 terawatt-hours.GlobeNewswire Inc. · Oct 8, 2024

W.P. Carey: Buy, Sell, or Hold?W.P. Carey has undergone a transformation by restructuring its real estate portfolio to make its business more resilient. The company sold off its office properties and reset its dividend, allowing it to reinvest capital into higher-quality income-producing properties. With a focus on industrial and warehouse properties, W.P. Carey is well-positioned to benefit from the ongoing demand for e-commerce and distribution centers.The Motley Fool · Sep 21, 2024

Cold storage REIT Lineage aims to raise up to $3.85 billion in US IPO By Reuters - Investing.comCold storage giant Lineage is seeking to raise up to $3.85 billion in its initial public offering on the Nasdaq Global Select Market. The real estate investment trust is backed by private equity firm Bay Grove Capital.Investing.com · Jul 16, 2024

The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocksA more selective small-cap index has consistently outperformed the Russell 2000MarketWatch · Jan 6, 2024

to start trading

LC

LCTXLineage Cell Therapeutics, Inc.

LCTX

Pay with—

Available Balance0.00

Your PositionYou don't own any LCTX yet.

Related Tickers

Earnings